Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

Abstract

Among patients with advanced melanoma, significantly longer overall survival occurred with combination therapy with nivolumab plus ipilimumab or with nivolumab alone than with ipilimumab alone. (Funded by Bristol-Myers Squibb and others; CheckMate 067 ClinicalTrials.gov number, NCT01844505 .).

Keywords

Affiliated Institutions

• KU Leuven BE
• Université Paris Cité FR
• The Netherlands Cancer Institute NL
• Assistance Publique – Hôpitaux de Paris FR
• Hospital General Universitario Gregorio Marañón ES
• The University of Melbourne AU
• Texas Oncology US
• Trans Tasman Radiation Oncology Group AU
• Hôpital Saint-Louis FR
• University of Padua IT
• Northwestern University PH
• Aix-Marseille Université FR
• Swansea University GB
• Istituti di Ricovero e Cura a Carattere Scientifico IT
• See-Spital CH
• Royal Marsden NHS Foundation Trust GB
• Princess Margaret Cancer Centre CA
• Melanoma Institute Australia AU
• University of Siena IT
• Peter MacCallum Cancer Centre AU
• German Cancer Research Center DE
• Délégation Paris 7 FR
• Deutschen Konsortium für Translationale Krebsforschung
• Inserm FR
• Bristol-Myers Squibb (United States) US
• European Institute of Oncology IT
• Olivia Newton-John Cancer Wellness & Research Centre AU
• Mylan (Switzerland) CH
• The Maria Sklodowska-Curie National Research Institute of Oncology PL
• University of Colorado Denver US
• University of Michigan US
• Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori IT
• Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" IT
• Dana-Farber Cancer Institute US
• Hôpital de la Timone FR
• Cancer Institute (WIA) IN
• Cornell University US
• The University of Sydney AU
• Memorial Sloan Kettering Cancer Center US

Related Publications